任意の製品分析
許可いただいた場合、プライバシーに配慮した限定的な分析を使用し、どのリサーチ経路が有効かを把握します。広告トラッカーやセッション録画は使用しません。この選択は設定で変更できます。詳しくは プライバシーポリシー.
Centene's biggest operational opportunity lies in Commercial Marketplace margin restoration and accelerated enterprise overhead reduction.
Consolidated operating margin failing to recover above 1.0% of revenue over the next 12 months as Medicaid expansion membership contracts from 20% to 18% of the portfolio.
We assign a Reduce rating to Centene Corporation. At the report-date price of $62.99 on October 2, 2026, the stock trades at a 22.4% premium to our Fair value of $51.46, offering an implied return of -18.3% that does not provide adequate compensation for ongoing Medicaid acuity mismatches and debt refinancing pressures.
The house rating on Centene Corporation is Reduce. For an investor, a Reduce rating indicates that current market pricing leaves shares overextended relative to fundamental business value and that investors should trim holdings or avoid allocating fresh capital. Centene is executing a broad operational and underwriting recovery after acute post-pandemic Medicaid eligibility redeterminations created severe cost mismatches. Although management has outlined structured turnaround initiatives across individual exchanges and administrative overhead, the market has anticipated a full earnings normalization ahead of verified operational delivery, leaving an insufficient safety buffer.
At the report-date price of $62.99 on October 2, 2026, Centene trades at a 22.4% premium to our Fair value of $51.46, generating an implied return of -18.3%. Furthermore, the report-date price trades 6.2% above our Potential value of $59.33, which reflects the upper valuation boundary under an accelerated operational turnaround. Because the prevailing price surpasses even our Potential value benchmark, we conclude that market optimism exceeds what can be supported by medium-term normalized cash generation.
The single risk that would fundamentally alter this perspective is persistent Medicaid medical loss ratio degradation driven by adverse selection and delayed state rate updates. In FY2025, elevated medical utilization produced a consolidated GAAP operating deficit of -$7,623,000,000. Centene's expansion membership is contracting from 20% toward 18% of the Medicaid portfolio, which removes lower-cost members and concentrates higher-acuity patients in the remaining pool. If state actuarial rate adjustments continue to lag ongoing medical inflation in behavioral healthcare and specialty drugs, consolidated operating margins will remain suppressed below 1.0%, extending underwriting losses across Centene's core $110,434,000,000 Medicaid business.578
The primary catalyst that could enable the investment thesis to work is rapid Commercial Marketplace margin expansion combined with structural overhead rationalization. Management targets FY2026 Marketplace pretax margins of 4.5% to 5.0% supported by meaningful CMS risk-adjustment receivables, alongside $480,000,000 in permanent SG&A savings from enterprise workforce optimization. If state Medicaid rate renewals catch up to medical trend and exchange pricing discipline holds, consolidated operating margins could normalize toward 3.5%, driving FY2027 diluted EPS toward $6.25 and lifting per-share value toward Potential value of $59.33. However, this upside potential remains secondary to the fundamental Fair value of $51.46 and the substantial underwriting headwinds Centene must overcome.15
Centene maintains dominant national scale in government-sponsored healthcare, generating $110,434,000,000 in Medicaid revenue in FY2025 representing 63.26% of consolidated revenues ($174,581,000,000). This massive enrollment volume provides local provider contracting leverage, clinical data advantages, and administrative overhead absorption across multi-state service regions.78
Centene executes targeted overhead rationalization through a $480,000,000 SG&A optimization program for FY2026, delivering a 10 basis points improvement in the enterprise adjusted SG&A rate. Centralized claims adjudication, digital self-service, and workforce streamlining lower per-member administrative costs within thin managed care industry benchmarks (3.0% operating margin).5
Entrenched regulatory procurement relationships across state Medicaid agencies and established distribution channels in individual health insurance exchanges ($42,003,000,000 Commercial revenue in FY2025) create significant structural switching costs for state sponsors. Non-operating peers like Baxter (BAX) operate in medical manufacturing with different economics, leaving Centene insulated from direct peer hardware competition.38
Reduce, because Centene trades at a 22.4% premium to its Fair value of $51.46, offering an implied return of -18.3% that does not compensate investors for Medicaid rate lag and debt refinancing risks.
Centene Corporation is a managed healthcare enterprise that delivers government-sponsored and commercial healthcare programs across the United States. The company provides healthcare products and services primarily through Medicaid, Medicare, and commercial products to individual members and state partners.
The organization operates across four reportable segments: Medicaid, Medicare, Commercial, and Other. The Medicaid, Medicare, and Commercial segments provide managed care coverage through government-subsidized programs, while the Other segment encompasses pharmacy operations, dental and vision services, clinical healthcare, behavioral health, and corporate centralized administration. In December 2025, the company entered into an agreement to divest its remaining Magellan Health businesses.
Centene maintains its corporate headquarters in St. Louis, Missouri, while operating localized health plans and claims processing facilities leased across the individual service regions and states it covers to meet regulatory standards.
Under a compounded stress scenario reflecting a 3.0 percentage point operating margin shock and persistent Medicaid acuity mismatches, Centene's financial turnaround faces severe structural friction. Following the FY2025 GAAP operating deficit of -$7,623,000,000 and net loss of -$6,674,000,000, an ongoing failure of state Medicaid actuarial rates to match medical inflation across the $110,434,000,000 Medicaid book would lock consolidated operating margins below 1.0%. In this environment, the non-recurrence of $0.50 per share in FY2026 adjusted EPS combined with adverse CMS Marketplace risk adjustments would compress FY2027 diluted EPS toward $4.63 (the consensus low). Furthermore, with $16,104,999,936 in total debt and $4.7B in senior notes maturing across years 2 and 3 at an observed pre-tax debt cost of 19.78%, refinancing at wide credit spreads would elevate net interest expenses above FY2025 levels ($678,000,000), consuming operating cash flow and driving terminal forward multiples down toward 9.0x, pulling fair value down to $38.18.
In FY2025, medical cost spikes drove GAAP operating income to -$7,623,000,000 on Medicaid revenue of $110,434,000,000. Ongoing Medicaid expansion attrition from 20% down toward 18% leaves higher-acuity members in the risk pool. If state actuarial rate adjustments lag behavioral health and high-cost specialty drug inflation, consolidated operating margins remain depressed below 1.0%, realizing the operating_margin_minus_3pp shock.578
投資判断を弱める5つの変化です。
Operating margin failing to recover above 1.0% indicates that state Medicaid rate updates remain insufficient to absorb elevated medical utilization in behavioral health and specialty drugs, delaying the underwriting turnaround,.
現在:-4.37% (FY2025 GAAP)
警戒条件< 1.0% in FY2026
Centene's narrow economic moat is anchored by its position as the largest Medicaid managed care provider in the United States, operating across highly regulated state programs that demand local provider network density, clinical compliance infrastructure, and specialized actuarial capabilities. In FY2025, consolidated revenue expanded to $174,581,000,000, led by $110,434,000,000 from Medicaid, $42,003,000,000 from Commercial individual exchanges, and $37,210,000,000 from Medicare. This massive enrollment volume establishes significant purchasing power when contracting with regional hospital systems and physician networks, creating barriers to entry for smaller or sub-scale managed care entrants.
Despite this franchise scale, Centene's economic moat is restricted to Narrow rather than Wide due to the regulatory nature of its margins and trailing economic returns. In FY2025, post-pandemic Medicaid eligibility redeterminations created severe underwriting mismatches where low-utilizing members disenrolled while high-acuity patients remained, driving a GAAP operating deficit of -$7,623,000,000 and net loss of -$6,674,000,000. Trailing ROIC of -0.60% failed to clear the company's 11.31% WACC, demonstrating that state-administered rate caps and actuarial lag can temporarily overwhelm scale advantages. A wide moat requires sustained structural returns above capital costs, which Centene has yet to re-establish post-redetermination.
The durability of Centene's competitive positioning is supported by its multi-year operational turnaround initiatives. Management has raised FY2026 Marketplace pretax margin targets to 4.5% to 5.0% and PDP margins to greater than 3.0%, while instituting an enterprise SG&A optimization program targeting $480,000,000 in opex savings. Furthermore, strong liquidity of $17,888,000,000 in cash and robust operating cash flow of $5,088,000,000 in FY2025 provide the capital required to navigate state rate cycles and maintain provider networks through underwriting stress.
Centene currently generates negative economic profit due to the severe FY2025 GAAP operating deficit of -$7,623,000,000 and net loss of -$6,674,000,000. Trailing ROIC of -0.60% (and third-party ROIC of -7.16%) sits well below the computed WACC of 11.31%, which is driven by a 9.35% cost of equity, a 19.78% pre-tax cost of debt, a 34.11% debt weight, and a 23.70% tax rate. While FY2025 operating cash flow was positive at $5,088,000,000 and cash liquidity stands at $17,888,000,000, structural economic value creation remains contingent on normalized operating margins recovering to 2.7% by FY2030 to generate returns exceeding the 11.31% hurdle rate.27
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Apply a terminal P/E to the dated forward path, then discount that future share value back to the analysis date.
None of the valuation methods used to calculate Fair value relies on a separate assumption about how long the competitive advantage lasts.
The highlighted cell is Fair value when every assumption sits at its base level ($51.46). Each row and column shows what Fair value becomes when one assumption moves.
A free-cash-flow drop test is not available in this run; use the discount-rate and terminal-growth grid as the primary valuation pressure test.
The base scenario represents the modal operating path with a target of $51.46 and an assigned probability of 55.0%, implying an expected return of -18.3% relative to $62.99. In this scenario, Centene successfully stabilizes its core Medicaid business as post-redetermination member attrition concludes and state actuarial rate adjustments gradually align with medical cost trends. Commercial Marketplace operations deliver pretax margins within the guided range, supported by positive risk-adjustment transfers. Overhead streamlining initiatives lower administrative expense ratios, supporting normalized operating margins and driving diluted earnings per share toward consensus expectations over the forecast horizon. Investors would confirm this path through consecutive quarters of stable medical loss ratios and realized administrative cost efficiencies.
A decisive operational beat driven by sustainable Medicaid rate adjustments and structural overhead savings would indicate faster restoration of normalized operating margins toward Fair value, narrowing the valuation gap relative to the price at analysis.
Operating performance tracking management targets confirms that the multi-year recovery is proceeding as modeled, leaving shares trading at the price at analysis well above Fair value with negative implied upside.
An earnings miss caused by widening Medicaid acuity mismatches or adverse risk-adjustment determinations would invalidate the operational margin turnaround, requiring an immediate downward revision to Fair value.
Centene displays a notable divergence between GAAP reported net deficits and strong underlying operating cash generation. Cash conversion remains exceptionally healthy, supported by consistent upfront premium receipts and expanding operational cash flow across state programs. However, earnings quality is tempered by the high proportion of one-time items embedded in near-term guidance, including non-recurring earnings benefits from prior-period estimate settlements and anticipated risk-adjustment transfer receivables from individual exchanges. True operational durability hinges on whether underlying medical cost trends normalize permanently rather than relying on annual actuarial adjustments and non-operating reserve releases.
Consensus revisions for FY2026 and FY2027 diluted earnings per share have remained largely flat post-earnings, reflecting market consensus aligning with management guidance. While top-line revenue estimates saw negligible non-material adjustments, sell-side expectations remain anchored around management targets, awaiting tangible confirmation of Medicaid margin stabilization in subsequent quarterly filings.
Medicaid represents the overwhelming core of total revenues, so unexpected medical acuity spikes directly compress operating margins and delay underwriting profitability.
Despite the severe FY2025 GAAP net loss of -$6,674,000,000 and operating loss of -$7,623,000,000, Centene generated robust operating cash flow of $5,088,000,000 and free cash flow of $4,321,000,000 after $767,000,000 in capital expenditures. In the first half of 2026 (ended June 30, 2026), operating cash flow accelerated to $7,956,000,000 and free cash flow reached $7,582,000,000 on revenue of $103,523,000,000 and capex of $374,000,000. Cash and cash equivalents totaled $17,888,000,000 at year-end 2025. This significant divergence between GAAP accounting losses and cash flow reflects substantial non-cash impairment and reserves, strong premium collections, and favorable claim timing differences.67
Centene's trailing return on invested capital was negative (-0.60% on operating income; -7.16% on third-party calculation) as a result of the $7,623,000,000 GAAP operating loss in FY2025 and net loss of -$6,674,000,000. However, ROIC trajectory is inflecting upward as underwriting pricing, state rate reconciliation, and $480,000,000 in SG&A reductions restore operating earnings toward guided FY2026 adjusted EPS exceeding $4.80 and FY2027 consensus of $5.35.
Trailing ROIC (-0.60%) sits substantially below the computed WACC of 11.31%, which is driven by a 9.35% cost of equity, a 19.78% pre-tax cost of debt, and a 34.11% debt weighting. Centene fails to generate positive economic value in FY2025, but normalized operating margins expanding toward 2.7% by FY2030 are modeled to narrow this negative spread.
| 売上高 | $174,581,000,000 |
|---|---|
| 売上原価 | $160,372,000,000 |
| 売上総利益 | $14,209,000,000 |
| 営業費用 | $21,832,000,000 |
| 営業利益 | -$7,623,000,000 |
| 営業外項目および税金 | $949,000,000 |
| 純利益 | -$6,674,000,000 |
| 総資産 | $76,747,000,000 |
|---|---|
| 現金 | $17,888,000,000 |
| 流動資産 | $40,370,000,000 |
| 負債合計 | $56,691,000,000 |
| 流動負債 | $36,696,000,000 |
| 株主資本 | $20,033,000,000 |
| 純利益 | $3,305,000,000 |
|---|---|
| 営業キャッシュ流入 | $4,758,000,000 |
| 減価償却費 | $1,241,000,000 |
| 株式報酬 | $212,000,000 |
| 営業キャッシュフロー | $154,000,000 |
| 営業キャッシュ流出 | $4,604,000,000 |
| 利用可能現金 | $17,614,000,000 |
| 期首現金 | $17,452,000,000 |
| 為替レートの影響 | $8,000,000 |
| 投資キャッシュ流出 | $1,052,000,000 |
| 設備投資 | $644,000,000 |
| その他の投資活動 | $408,000,000 |
| 財務キャッシュ流出 | $2,406,000,000 |
| 期末現金 | $14,156,000,000 |
| 投資キャッシュフロー | -$1,052,000,000 |
| 財務キャッシュフロー | -$2,406,000,000 |
出典: SEC EDGAR · 提出日 2026-02-17 · SEC EDGAR
| 事業セグメント別売上高 | 売上高 | 構成比 | 前年比 |
|---|---|---|---|
| Medicaid | $1104.3億 | 56.7% | 8.9% |
| Commercial | $420億 | 21.6% | 24.6% |
| Medicare | $372.1億 | 19.1% | 61.6% |
| All Other Segments | $51.3億 | 2.6% | 4.3% |
2026-10-04の分析で使用した時点財務データ。
| 期間 | 売上高 | EBITDA | 純利益 | 営業キャッシュフロー | フリーキャッシュフロー | 設備投資 | 減価償却費 | 株式報酬 | 自社株買い | 支払配当金 | 純有利子負債調達 | 投資キャッシュフロー | 財務キャッシュフロー | 期首現金 | 期末現金 | 現金および投資 | 総負債 | 営業利益率 | ROIC | WACC | ROIC−WACCスプレッド |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $375.8億 | $16.6億 | $5.6億 | $18.5億 | $15.5億 | $3.1億 | $2.8億 | $1.5億 | $6300万 | $0 | — | -$24.7億 | $27.2億 | — | $39.4億 | $44.4億 | $47.8億 | 3.4% | — | 4.3% | — |
| 2017-12-31 | $456.2億 | $17.5億 | $8.3億 | $14.9億 | $10.7億 | $4.2億 | $3.6億 | $1.4億 | $6500万 | $6600万 | — | -$12.5億 | -$8200万 | $39.4億 | $40.9億 | $46億 | $48.3億 | 2.6% | — | 4.9% | — |
| 2018-12-31 | $564.4億 | $22.1億 | $9億 | $12.3億 | $5.6億 | $6.8億 | $5億 | $1.5億 | $7100万 | $60.8億 | — | -$45.9億 | $46.1億 | $40.9億 | $53.5億 | $60.6億 | $68.5億 | 2.6% | — | 5.8% | — |
| 2019-12-31 | $703.6億 | $28.4億 | $13.2億 | $14.8億 | $7.5億 | $7.3億 | $6.4億 | $1.8億 | $7500万 | — | — | -$15.3億 | $68.3億 | $53.5億 | $121.3億 | $129.9億 | $138.6億 | 2.5% | — | 4.3% | — |
| 2020-12-31 | $1038億 | $47.6億 | $18.1億 | $55億 | $46.3億 | $8.7億 | $12.6億 | $2.8億 | $6.3億 | — | — | -$69.6億 | $2.6億 | $121.3億 | $109.6億 | $123.8億 | $168.8億 | 3.0% | — | 3.0% | — |
| 2021-12-31 | $1179.8億 | $38.1億 | $13.5億 | $42.1億 | $33億 | $9.1億 | $13.4億 | $2億 | $3億 | $3500万 | — | -$33億 | $13.6億 | $109.6億 | $132.1億 | $146.6億 | $190.3億 | 1.5% | — | 3.8% | — |
| 2022-12-31 | $1354.8億 | $40.6億 | $12億 | $62.6億 | $52.6億 | $10億 | $14.3億 | $2.3億 | $31億 | — | -$11.4億 | -$29.2億 | -$42億 | $132.1億 | $123.3億 | $144億 | $181.8億 | 1.0% | — | 6.2% | — |
| 2023-12-31 | $1401億 | $29.3億 | $27億 | $80.5億 | $72.5億 | $8億 | $12.9億 | $2.2億 | $16.3億 | $8800万 | $1900万 | -$11.9億 | -$16.6億 | $123.3億 | $174.5億 | $196.5億 | $179.6億 | 2.1% | — | 5.5% | — |
| 2024-12-31 | $1455.1億 | $62億 | $33.1億 | $1.5億 | -$4.9億 | $6.4億 | $12.4億 | $2.1億 | $31.2億 | — | $6.8億 | -$10.5億 | -$24.1億 | $174.5億 | $141.6億 | $166.9億 | $186.4億 | 2.2% | — | 5.8% | — |
| 2025-12-31 | $1745.8億 | -$51.4億 | -$66.7億 | $50.9億 | $43.2億 | $7.7億 | $12.8億 | $2億 | $4.8億 | — | -$11.5億 | $4.7億 | -$16.2億 | $141.6億 | $179.6億 | $203.2億 | $174.9億 | -4.4% | — | — | — |
Centene Corporation (CNC) trades at 11.2x forward earnings against a peer median of 17.2x. Its EV/EBITDA of 4.4x compares with a peer median of 15.1x. The comparison uses 4 peers: Moderna Inc., Baxter International Inc., Natera Inc. and Charles River Laboratories International Inc., as of 2026-10-04.
The healthcare support services sector operates with an industry capex-to-revenue ratio of 0.9% (0.009) and a capex-to-depreciation ratio of 0.81 (81.0%), confirming that physical capital capacity is not a primary capital sink. In FY2025, Centene invested $767,000,000 in capex against $1,275,000,000 in depreciation and amortization on $174,581,000,000 in revenue. Because industrial capacity, lead-time, and supply constraints are not traditional bottlenecks in managed care, the cycle is demand-led and evidence-limited regarding physical capital, governed instead by statutory underwriting capital reserves and state rate reconciliation cycles.7
In an industry upcycle, state Medicaid actuarial rate adjustments catch up and exceed medical inflation, expanding gross margins across Centene's $110,434,000,000 Medicaid base. Concurrently, stable ACA risk-adjustment dynamics allow Marketplace margins to sustain at 4.5% to 5.0%, driving consolidated operating margins toward the sector benchmark of 3.0% and lifting FY2027 diluted EPS toward $6.25.
In an industry downcycle, prolonged Medicaid eligibility redeterminations and state budget tightening compress membership while leaving disproportionately high-acuity patients in managed care pools. As medical cost inflation in behavioral health and specialty drugs persists, state rate updates lag by 12 to 24 months, depressing consolidated operating margins below 1.0% and pushing FY2027 diluted EPS toward $4.63.
Centene holds dominant market share in government-sponsored healthcare, particularly Medicaid where its $110.43B in FY2025 revenue represents 63.26% of consolidated revenues ($174.58B),. While non-operating peer comparables like Baxter (BAX) operate in medical equipment with high gross margins (34.10%), Centene's positioning is strictly tied to state healthcare procurement and individual exchange administration. Management's 2026 turnaround initiatives ($480M SG&A reduction) position the firm to recover from its FY2025 GAAP operating loss of -$7,623,000,000 faster than smaller, single-state competitors.3578
Given the committee's Reduce rating, an underweight exposure of 0-1% is warranted. The share price of $62.99 stands at a 22.4% premium to Fair value ($51.46), implying an upside of -18.3%. While Centene generates strong operating cash flow ($5,088,000,000 in FY2025) and holds $17,888,000,000 in cash liquidity, trailing GAAP operating losses of -$7,623,000,000 and debt refinancing obligations across $16,104,999,936 total debt create an asymmetric risk profile that does not justify market-weight positioning.47
Risk management focuses on capital preservation given the stock's current 22.4% premium to fair value ($51.46) and the company's $16,104,999,936 debt burden. Portfolio managers should enforce strict position caps (underweight at 0-1%), use market rallies toward 52-week highs ($69.63) as liquidity events to trim holdings, and continuously monitor state regulatory filings for signs of actuarial rate delays or risk-adjustment payment disputes. Solvency risk is mitigated by $17,888,000,000 in balance sheet cash, but valuation multiple compression remains the primary risk factor for equity holders.
Centene trades at a 22.4% premium to its Fair value of $51.46, yielding an implied return of -18.3%. Trailing GAAP operating income was -$7,623,000,000 in FY2025 and trailing return on capital falls short of its 11.31% cost of capital. Value investors should avoid establishing new positions until the valuation reflects an adequate margin of safety.27
Centene pays no regular dividend (0% payout ratio), directing excess cash flow toward debt service on its $16,104,999,936 debt burden and operational capital expenditures. Without cash income support and facing negative implied returns, the stock offers an unfavorable profile for income-oriented portfolios.4
Existing turnaround investors may hold trimmed positions to observe execution of the $480,000,000 enterprise optimization program and guided Marketplace pretax margin recovery of 4.5% to 5.0%. However, fresh buying should be suspended because $0.50 of FY2026 adjusted EPS is non-recurring and share prices sit above our Potential value ceiling of $59.33.5
We recommend reducing exposure to Centene Corporation. The stock trades at $62.99 as of October 2, 2026, representing a 22.4% premium to our fundamental Fair value of $51.46 and an implied return of -18.3%. While operational turnaround measures are underway, the current share price leaves no margin of safety against Medicaid acuity lag and heavy balance-sheet debt refinancing.4
Investors currently holding Centene shares should use recent market strength to trim positions and reallocate capital into healthcare opportunities offering favorable risk-adjusted returns and positive economic profit above their cost of capital.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
In the downside scenario, Medicaid underwriting margins remain constrained as state rate adjustments lag underlying medical cost inflation in behavioral health and specialty pharmaceuticals. Persistent member acuity headwinds and state eligibility tightening prevent normalized operating margins from recovering. Concurrently, competitive pricing pressures in Commercial exchanges reduce Marketplace pretax margins, while one-time earnings items roll off without immediate replacement. Refinancing upcoming debt maturities under elevated credit spreads expands net interest obligations, impairing free cash flow generation and leading to multiple contraction across the managed care sector.
Consensus projects FY2027 revenue contracting -1.62% to $192,753,367,610 due to Medicaid expansion attrition and state tightening. If state contract procurement losses or federal policy shifts accelerate enrollment shrinkage across the $110.43B Medicaid portfolio, revenue contraction deeper than -2.0% annually over 5 years erodes operating leverage on fixed overhead.158
Centene carries $16,104,999,936 in total debt with pre-tax cost of debt observed at 19.78%, while cash conversion and margin durability remain pressured by underwriting volatility. Over $4.7B in debt matures across years 2 and 3; refinancing at high spreads combined with persistent underwriting volatility would force terminal multiple compression below 9.0x forward earnings.24
Segment pretax margin falling below 2.5% signals adverse CMS risk-adjustment transfer determinations or market share erosion from aggressive competitor pricing, erasing over $800M in expected operating profit,.
現在:4.5% - 5.0% (guided FY2026)
警戒条件< 2.5% in FY2026 or FY2027
Medicaid revenue contracting below $100B indicates significant RFP procurement losses in key state renewals or accelerated expansion attrition beyond 18% portfolio guidance, eroding fixed cost overhead absorption,.
現在:$110,434,000,000 (FY2025)
警戒条件< $100,000,000,000 in FY2026
Realized administrative savings falling short of $350M annualized indicates workforce restructuring friction, preventing the 10 bps enterprise SG&A efficiency needed to support normalized operating margins,.
現在:$480,000,000 (guided FY2026)
警戒条件< $350,000,000 realized annualized
Medicaid HBR exceeding 91.0% confirms persistent acuity cost pressure in behavioral health, home health, and specialty drugs that exceeds state reimbursement, expanding underwriting deficits,.
現在:Consistent with guidance baseline (FY2026)
警戒条件> 91.0% consolidated Medicaid HBR
| medium |
| 12-24 months |
| Disciplined state-by-state pricing strategy, enhanced HCC risk-coding documentation, and balanced benefit designs to manage risk pool selection,.5 |
| Concentrated Debt Maturities Refinancing Under Elevated Borrowing Costs | medium | 24-36 months | Deploying cash reserves ($17,888,000,000) and operating cash generation ($5,088,000,000 in FY2025) to selectively retire debt and manage credit spreads.7 |
Project revenue, apply a terminal EV/revenue multiple, discount enterprise value, subtract net debt, and divide by diluted shares.
Solve for the growth rate that makes the model value equal the report-date share price.
The bull scenario outlines an accelerated recovery path toward Potential value of $59.33, reflecting a target of $59.33 and a probability of 20.0%, delivering a potential return of -5.8% from $62.99. This outcome requires state Medicaid rate increases to exceed medical inflation, fully restoring underwriting profitability across the core portfolio. Concurrently, favorable risk-adjustment determinations lift Commercial Marketplace margins beyond guided expectations, while enterprise overhead streamlining generates structural administrative cost reductions above initial targets. Robust cash conversion accelerates debt paydown, de-risking upcoming maturities and prompting market multiple expansion toward leading managed care peers. Disconfirmation would occur if state rate updates fail to exceed trend or exchange competition erodes pricing power.
Commercial exchange margins provide immediate operating profit expansion during the Medicaid turnaround, and adverse risk-adjustment reconciliations would eliminate hundreds of millions in expected pre-tax profit.
Structural administrative expense reduction is essential to expanding consolidated operating margins toward industry benchmarks on high revenue volume.
Because managed care contracts are regulated, forward profitability requires state partners to grant composite rate updates that fully match or exceed underlying medical cost trends.
Concentrated debt maturities over the coming fiscal years create refinancing risk under high prevailing interest rates, which would expand interest expense and diminish net income.
| $177.08B |
| $182.40B |
| $187.87B |
| Operating income | $4.74B | $4.66B | $4.78B | $4.92B | $5.07B |
| NOPAT | $3.62B | $3.56B | $3.65B | $3.76B | $3.87B |
| Residual cash after reinvestment policy | $3.26B | $3.20B | $3.29B | $3.38B | $3.49B |
| Revenue growth | 0.6% | -1.6% | 2.5% | 3.0% | 3.0% |
| Operating margin | 2.7% | 2.7% | 2.7% | 2.7% | 2.7% |
| Tax rate | 23.7% | 23.7% | 23.7% | 23.7% | 23.7% |
| Reinvestment rate | 10.0% | 10.0% | 10.0% | 10.0% | 10.0% |
| Terminal growth | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% |
Centene's capital allocation strategy prioritizes balance sheet liquidity, debt service, and selective share repurchases over dividends. Centene pays no regular dividend (0% payout ratio), preserving cash flow to support regulatory capital requirements across state health plans. Total debt stood at $16,104,999,936 as of October 2026 ($16,030,000,000 long-term debt as of June 30, 2026). With debt maturities concentrating $2,316,000,000 in year 2 and $2,400,000,000 in year 3, capital allocation must remain conservative, directing portions of annual operating cash generation ($5,088,000,000 in FY2025) toward scheduled note repayments to mitigate refinancing at an observed pre-tax debt cost of 19.78%. Share count is assumed to contract modestly at -0.3% annually from 493,995,000 shares.
Operating cash flow of $5,088,000,000 in FY2025 and $7,956,000,000 in the first half of 2026 contrasted sharply with the FY2025 GAAP net loss of -$6,674,000,000.
Solvency risk is heavily mitigated by $17,888,000,000 in cash liquidity, allowing Centene to fund operations and enterprise restructuring without dilutive equity financing.
Centene carries $16,104,999,936 in total debt with an observed pre-tax cost of debt of 19.78% and over $4.7B maturing across years 2 and 3.
Refinancing at current high interest spreads risks expanding net interest expense well above FY2025 levels of $678,000,000, necessitating disciplined debt paydown to protect net margins.
On a $174,581,000,000 consolidated revenue base, each 50 basis points of consolidated operating margin improvement generates approximately $873,000,000 in pre-tax operating income.
Targeted SG&A reductions of $480,000,000 combined with Marketplace margins reaching 4.5% to 5.0% provide substantial operating leverage to drive EPS toward $5.35 in FY2027.
| マージン |
|---|
| CNC | Centene Corporation | $31.1B | 11.2x | 0.2x | 4.4x | -20.4% | — |
| MRNA | Moderna Inc. | $75.9B | 34.0x | -39.0% | -5.6% | ||
| BAX | Baxter International Inc. | $12.1B | 11.5x | 1.1x | 10.4x | -14.4% | 14.4% |
| NTRA | Natera Inc. | $59.1B | 21.9x | -12.5% | -10.3% | ||
| CRL | Charles River Laboratories International Inc. | $13.9B | 22.8x | 3.5x | 19.7x | -7.5% | 15.1% |
| Specialty Drug and Behavioral Health Cost Inflation | negative | Elevated utilization in behavioral health and expensive GLP-1/specialty pharmaceuticals increases medical benefit expense pressure, requiring ongoing administrative controls and retroactive rate advocacy with state sponsors. |
| Persistent Medicaid Rate Lag and Margin Compression |
| Evaluate upgrading to overweight positioning if Medicaid rate reconciliation is fundamentally intact |
| If market pricing fully reflects persistent margin compression and rate lag, valuation offers highly favorable risk-adjusted asymmetry. |
| Downgrade near-term earnings expectations and trim position, signaling failure of risk adjustment receivables or exchange pricing discipline.5 |
| Medicaid Expansion Membership | < 17.5% of total portfolio | Re-evaluate revenue scale and overhead absorption assumptions, indicating accelerated member disenrollment beyond management expectations.5 |
| Enterprise Optimization SG&A Savings | < $100,000,000 quarterly run-rate | Lower medium-term normalized EBIT margin projections toward 2.0%, reflecting restructuring execution delays.5 |
